Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

BackgroundData on the use of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation are limited. The current study aimed to assess the efficacy of ICIs in EGFR-mutant advanced NSCLC and explore the relevant in...

Full description

Saved in:
Bibliographic Details
Main Authors: Tian Tian, Min Yu, Juan Li, Maoqiong Jiang, Daiyuan Ma, Shubin Tang, Zhiyu Lin, Lin Chen, Youling Gong, Jiang Zhu, Qiang Zhou, Meijuan Huang, You Lu
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
non–small cell lung cancer
immune checkpoint inhibitor
tyrosine kinase inhibitor
epidermal growth factor receptor
resistance
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/69a13cda47364735a4dda48c6d0895f8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/69a13cda47364735a4dda48c6d0895f8

Similar Items